Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China.
Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
J Biomed Nanotechnol. 2022 Apr 1;18(4):1064-1074. doi: 10.1166/jbn.2022.3324.
Cytokine release syndrome (CRS) is a severe complication of infectious diseases like Coronavirus disease 2019 (COVID-19) that cause serious damage to public health. Currently, supportive therapy is still the main therapeutic strategy exists for CRS treatment. Here, we show the potential of macrophage membrane-derived biomimetic nanoparticles for CRS treatment. By fusing macrophage membrane on the surface of the PLGA nano core, we constructed biomimetic nanoparticles that inherited the membrane receptors from the "parental" macrophages, enabling the neutralization of CRS-related cytokines. We compared three types of macrophage membranes to screen out more effective biomimetic nanoparticles for CRS treatment. Our results show that M0 macrophage membrane-derived biomimetic nanoparticles could neutralize pro-inflammatory cytokines involved in CRS to the greatest extent and reduce organ damage in a mouse model.
细胞因子释放综合征(CRS)是一种严重的传染病并发症,如 2019 年冠状病毒病(COVID-19),对公共健康造成严重损害。目前,支持性治疗仍然是治疗 CRS 的主要治疗策略。在这里,我们展示了巨噬细胞膜衍生的仿生纳米粒子治疗 CRS 的潜力。通过在 PLGA 纳米核表面融合巨噬细胞膜,我们构建了仿生纳米粒子,从“亲代”巨噬细胞中继承了膜受体,从而能够中和与 CRS 相关的细胞因子。我们比较了三种类型的巨噬细胞膜,以筛选出更有效的用于治疗 CRS 的仿生纳米粒子。结果表明,M0 巨噬细胞膜衍生的仿生纳米粒子能够最大程度地中和参与 CRS 的促炎细胞因子,并减轻小鼠模型中的器官损伤。